Ambrx
Clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.
About
Technology stack
detected 2026-05-23No comments yet. Be the first to share your take.
What does Ambrx do?
Ambrx is a clinical-stage biopharmaceutical company that utilizes a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). Their technology allows for the incorporation of synthetic amino acids into proteins, enabling site-specific, homogenous, and stable conjugation. This platform aims to overcome limitations of traditional conjugation technologies and create precision biologics with optimized safety and efficacy for treating var…
How much funding has Ambrx raised?
Ambrx has raised a total of $462M in funding. The most recent round on record is ATM.
Where is Ambrx headquartered?
Ambrx is headquartered in San Diego, United States.
When was Ambrx founded?
Ambrx was founded in 2003.
What industry does Ambrx operate in?
Ambrx operates in Biotechnology, Drug Discovery, Oncology, Antibody-Drug Conjugates (ADCs), Precision Medicine, Synthetic Biology.
What is Ambrx's current status?
Ambrx's current operating status is: Inactive.